drugset / Trial / NCT03835819
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
Phase 2
Active not recruiting
18 enrolled
Dana-Farber Cancer Institute
ImmunoGen, Inc. · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a drug combination as a possible treatment for endometrial cancer. The drugs involved in this study are: * mirvetuximab soravtansine (IMGN853) * pembrolizumab
Timeline
- Start
- 2020-01-02
- Primary completion
- 2024-06-04
- Completion
- 2027-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirvetuximab Soravtansine | Other / unclassified | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |